These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 34319750)

  • 1. Highly Multiplexed Kinase Profiling in Spleen with Targeted Mass Spectrometry Reveals Kinome Plasticity across Species.
    Marholz LJ; Federspiel JD; Suh H; Fernandez Ocana M
    J Proteome Res; 2021 Sep; 20(9):4272-4283. PubMed ID: 34319750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer.
    Hoffman MA; Fang B; Haura EB; Rix U; Koomen JM
    J Proteome Res; 2018 Jan; 17(1):63-75. PubMed ID: 29164889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A targeted quantitative proteomics strategy for global kinome profiling of cancer cells and tissues.
    Xiao Y; Guo L; Wang Y
    Mol Cell Proteomics; 2014 Apr; 13(4):1065-75. PubMed ID: 24520089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
    Kamath AV; Wang J; Lee FY; Marathe PH
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical proteomics reveals target selectivity of clinical Jak inhibitors in human primary cells.
    Eberl HC; Werner T; Reinhard FB; Lehmann S; Thomson D; Chen P; Zhang C; Rau C; Muelbaier M; Drewes G; Drewry D; Bantscheff M
    Sci Rep; 2019 Oct; 9(1):14159. PubMed ID: 31578349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the novel broad-spectrum kinase inhibitor CTx-0294885 as an affinity reagent for mass spectrometry-based kinome profiling.
    Zhang L; Holmes IP; Hochgräfe F; Walker SR; Ali NA; Humphrey ES; Wu J; de Silva M; Kersten WJ; Connor T; Falk H; Allan L; Street IP; Bentley JD; Pilling PA; Monahan BJ; Peat TS; Daly RJ
    J Proteome Res; 2013 Jul; 12(7):3104-16. PubMed ID: 23692254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Optimized Chromatographic Strategy for Multiplexing In Parallel Reaction Monitoring Mass Spectrometry: Insights from Quantitation of Activated Kinases.
    Urisman A; Levin RS; Gordan JD; Webber JT; Hernandez H; Ishihama Y; Shokat KM; Burlingame AL
    Mol Cell Proteomics; 2017 Feb; 16(2):265-277. PubMed ID: 27940637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broad-Spectrum Kinase Profiling in Live Cells with Lysine-Targeted Sulfonyl Fluoride Probes.
    Zhao Q; Ouyang X; Wan X; Gajiwala KS; Kath JC; Jones LH; Burlingame AL; Taunton J
    J Am Chem Soc; 2017 Jan; 139(2):680-685. PubMed ID: 28051857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia.
    Cooper MJ; Cox NJ; Zimmerman EI; Dewar BJ; Duncan JS; Whittle MC; Nguyen TA; Jones LS; Ghose Roy S; Smalley DM; Kuan PF; Richards KL; Christopherson RI; Jin J; Frye SV; Johnson GL; Baldwin AS; Graves LM
    PLoS One; 2013; 8(6):e66755. PubMed ID: 23826126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Large-scale proteomics analysis of the human kinome.
    Oppermann FS; Gnad F; Olsen JV; Hornberger R; Greff Z; Kéri G; Mann M; Daub H
    Mol Cell Proteomics; 2009 Jul; 8(7):1751-64. PubMed ID: 19369195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimized chemical proteomics assay for kinase inhibitor profiling.
    Médard G; Pachl F; Ruprecht B; Klaeger S; Heinzlmeir S; Helm D; Qiao H; Ku X; Wilhelm M; Kuehne T; Wu Z; Dittmann A; Hopf C; Kramer K; Kuster B
    J Proteome Res; 2015 Mar; 14(3):1574-86. PubMed ID: 25660469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dasatinib, imatinib and staurosporine capture compounds - Complementary tools for the profiling of kinases by Capture Compound Mass Spectrometry (CCMS).
    Fischer JJ; Dalhoff C; Schrey AK; Graebner OY; Michaelis S; Andrich K; Glinski M; Kroll F; Sefkow M; Dreger M; Koester H
    J Proteomics; 2011 Dec; 75(1):160-8. PubMed ID: 21664307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute lymphoid and gastrointestinal toxicity induced by selective p38alpha map kinase and map kinase-activated protein kinase-2 (MK2) inhibitors in the dog.
    Morris DL; O'Neil SP; Devraj RV; Portanova JP; Gilles RW; Gross CJ; Curtiss SW; Komocsar WJ; Garner DS; Happa FA; Kraus LJ; Nikula KJ; Monahan JB; Selness SR; Galluppi GR; Shevlin KM; Kramer JA; Walker JK; Messing DM; Anderson DR; Mourey RJ; Whiteley LO; Daniels JS; Yang JZ; Rowlands PC; Alden CL; Davis JW; Sagartz JE
    Toxicol Pathol; 2010 Jun; 38(4):606-18. PubMed ID: 20448081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.
    Salphati L; Pang J; Plise EG; Lee LB; Olivero AG; Prior WW; Sampath D; Wong S; Zhang X
    Drug Metab Dispos; 2012 Sep; 40(9):1785-96. PubMed ID: 22696419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver dihydropyrimidine dehydrogenase activity in human, cynomolgus monkey, rhesus monkey, dog, rat and mouse.
    Sludden J; Hardy SC; VandenBranden MR; Wrighton SA; McLeod HL
    Pharmacology; 1998 May; 56(5):276-80. PubMed ID: 9597696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SB-239063, a potent and selective inhibitor of p38 map kinase: preclinical pharmacokinetics and species-specific reversible isomerization.
    Ward KW; Proksch JW; Azzarano LM; Salyers KL; McSurdy-Freed JE; Molnar TM; Levy MA; Smith BR
    Pharm Res; 2001 Sep; 18(9):1336-44. PubMed ID: 11683250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An atlas of the catalytically active liver and spleen kinases in chicken identified by chemoproteomics.
    Nanduri B; Gresham CR; Hui WW; Ou M; Bailey RH; Edelmann MJ
    J Proteomics; 2020 Aug; 225():103850. PubMed ID: 32502695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity-Based Protein Profiling Reveals Potential Dasatinib Targets in Gastric Cancer.
    Choi KM; Cho E; Bang G; Lee SJ; Kim B; Kim JH; Park SG; Han EH; Chung YH; Kim JY; Kim E; Kim JY
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinase inhibitor profiling using chemoproteomics.
    Schirle M; Petrella EC; Brittain SM; Schwalb D; Harrington E; Cornella-Taracido I; Tallarico JA
    Methods Mol Biol; 2012; 795():161-77. PubMed ID: 21960222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.